參考文獻(xiàn)/References:
[1] 國(guó)家衛(wèi)生健康委員會(huì)辦公廳,國(guó)家中醫(yī)藥管理局辦公室.關(guān)于印發(fā)新型冠狀病毒肺炎診療方案(試行第七版)的通知:國(guó)衛(wèi)辦醫(yī)函〔2020〕184號(hào)[A/OL].(2020-03-04)[2020-03-05].http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[2] XU X,YU C C,QU J,et al.Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2[J].Eur J Nucl Med Mol Imaging,2020.DOI: 10.1007/s00259-020-04735-9.
[3] WANG D W,HU B,HU C,et al.Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,China[J].JAMA,2020.DOI:10.1001/jama.2020.1585.
[4] ZHOU W,LIU Y,TIAN D,et al.Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia[J].Signal Transduct Target Ther,2020.DOI:10.1038/s41392-020-0127-9.
[5] GUAN W J,NI Z Y,HU Y,et al.Clinical characteristics of coronavirus disease 2019 in China[J].N Engl J Med,2020. doi:10.1056/NEJMoa2002032.
[6] HARDY R S,RAZA K,COOPER M S.Therapeutic glucocorticoids:mechanisms of actions in rheumatic diseases[J].Nat Rev Rheumatol,2020,16(3).133-144.
[7] HARDY R S,ZHOU H,SEIBEL M J,et al.Glucocorticoids and bone:consequences of endogenous and exogenous excess and replacement therapy[J].Endocr Rev,2018,39(5):519-548.
[8] CUI L Q,ZHUANG Q Y,LIN J,et al.Multicentric epidemiologic study on six thousand three hundred and ninety five cases of femoral head osteonecrosis in China[J].Int Orthop,2016,40(2):267-276.
[9] GUO K J,ZHAO F C,GUO Y,et al.The influence of age,gender and treatment with steroids on the incidence of osteonecrosis of the femoral head during the management of severe acute respiratory syndrome:a retrospective study[J].Bone Joint J,2014,96-B(2):259-262.
[10] 羅月中,李蕓,李勇,等.補(bǔ)腎健骨法預(yù)防腎病綜合征患者激素性股骨頭壞死臨床研究[J].中醫(yī)正骨,2011,23(1):3-6.
[11] XU Z,SHI L,WANG Y J,et al.Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J].Lancet Respir Med,2020.DOI:10.1016/S2213-2600(20)30076-X.
[12] 劉茜,王榮帥,屈國(guó)強(qiáng),等.新型冠狀病毒肺炎死亡尸體系統(tǒng)解剖大體觀察報(bào)告[J].法醫(yī)學(xué)雜志,2020,36(1):1-3.DOI:10.12116/j.issn.1004-5619.2020.01.00.
[13] HUANG C L,WANG Y M,LI X W,et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J].Lancet,2020,395(10223):497-506.
[14] CHEN N,ZHOU M,DONG X,et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:a descriptive study[J]Lancet,2020,395(10223):507-513.
[15] 王玉光,齊文升,馬家駒,等.新型冠狀病毒肺炎中醫(yī)臨床特征與辨證治療初探[J].中醫(yī)雜志,2020,61(4):281-285.
[16] 黃雄杰,賴敏,賈春華,等.新型冠狀病毒肺炎(NCP)之中醫(yī)論治觀[J].世界中醫(yī)藥,2020,15(2):134-139.
[17] 李非,李盛華,周明旺,等.激素性股骨頭壞死發(fā)病機(jī)制中醫(yī)理論探析及中醫(yī)體質(zhì)研究現(xiàn)狀[J].西部中醫(yī)藥,2018,31(2):135-137.
[18] 魏秋實(shí),何偉,張慶文,等.股骨頭壞死中醫(yī)證型分布規(guī)律的文獻(xiàn)研究和系統(tǒng)評(píng)價(jià)[J].中華關(guān)節(jié)外科雜志(電子版),2013,7(3):369-372.
[19] 魏秋實(shí),李子祺,袁穎嘉,等.“標(biāo)本兼治”理論在股骨頭壞死中醫(yī)藥治療中的指導(dǎo)作用[J].中醫(yī)正骨,2020,32(1):56-59.
[20] HONG N,DU X K.Avascular necrosis of bone in severe acute respiratory syndrome[J].Clin Radiol,2004,59(7):602-608.
[21] 李子榮. 股骨頭壞死成功保髖新理念[J].中醫(yī)正骨,2018,30(10):1-3.
[22] COHEN-ROSENBLUM A,CUI Q J.Osteonecrosis of the Femoral Head[J].Orthop Clin North Am,2019,50(2):139-149.
[23] SAITO M, UESHIMA K, FUJIOKA M, et al.Corticosteroid administration within 2 weeks after renal transplantation affects the incidence of femoral head osteonecrosis[J].Acta Orthop,2014,85(3):266-270.
[24] 李子榮,孫偉,屈輝,等.皮質(zhì)類固醇與骨壞死關(guān)系的臨床研究[J].中華外科雜志,2005,43(16):1048-1053.
[25] OBITSU S,AHMED N,NISHITSUJI H,et al.Potential enhancement of osteoclastogenesis by severe acute respiratory syndrome coronavirus 3a/X1 protein[J].Arch Virol,2009,154(9):1457-1464.
[26] QUEIROZ-JUNIOR C M, SANTOS A C P M, GALVÃO L, et al. The angiotensin converting enzyme 2/angiotensin-(1-7)/Mas Receptor axis as a key player in alveolar bone remodeling[J].Bone,2019,128:115041.
[27] YAN R H,ZHANG Y Y,GUO Y Y,et al.Structural basis for the recognition of the 2019-nCoV by human ACE2[J].bioRxiv,2020.Doi: https://doi.org/10.1101/2020.02.19.956946.
[28] LU R,ZHAO X,LI J,et al.Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J].Lancet,2020,395(10224):565-574.
[29] HATANAKA H,MOTOMURA G,IKEMURA S,et al.Differences in magnetic resonance findings between symptomatic and asymptomatic pre-collapse osteonecrosis of the femoral head[J].Eur J Radiol,2019,112:1-6.
[30] 何曉銘,龔水帝,龐鳳祥,等.抵抗素水平與股骨頭壞死塌陷進(jìn)程的相關(guān)性[J].實(shí)用醫(yī)學(xué)雜志,2019,35(4):579-583.
中醫(yī)正骨2020年3月第32卷第3期 J Trad Chin Orthop Trauma,2020,Vol.32,No.3(總211)
(總212)中醫(yī)正骨2020年3月第32卷第3期 J Trad Chin Orthop Trauma,2020,Vol.32,No.3
[31] HE M C,GONG S D,CHEN X J,et al.Plasma C-terminal cross-linking telopeptide of type Ⅱ collagen as a biomarker in advanced stages of femoral head osteonecrosis[J].Biomed Pharmacother,2019,111:1213-1220.
[32] GONG S D,CHEN X J,CHEN Z Q,et al.Elevated plasma cartilage oligomeric matrix protein(COMP)level are associated with the progression of non-traumatic osteonecrosis of femoral head[J].Clin Chim Acta,2019,490:214-221.
[33] CHEN X J,YANG F,CHEN Z Q,et al.Association of reduced sclerostin expression with collapse process in patients with osteonecrosis of the femoral head[J].Int Orthop,2018,42(7):1675-1682.
[34] 魏秋實(shí),何偉,張慶文,等.基于X線片建立股骨頭壞死新分型體系的臨床意義[J]. 中華關(guān)節(jié)外科雜志(電子版),2018,12(6):849-856.
[35] LIU T S,MA J C,SU B,et al.A 12-year follow-up study of combined treatment of post-severe acute respiratory syndrome patients with femoral head necrosis[J].Ther Clin Risk Manag,2017,13:1449-1454.
[36] WANG W, ZHANG N, GUO W, et al. Combined pharmacotherapy for osteonecrosis of the femoral head after severe acute respiratory syndrome and interstitial pneumonia:two and a half to fourteen year follow-up[J].Int Orthop,2018, 42(7):1551-1556.
[37] 何偉.精確診斷前提下股骨頭壞死非手術(shù)治療實(shí)踐[J].臨床外科雜志,2017,25(8):580-582.
[38] 何偉.如何把握股骨頭壞死患者的保髖治療時(shí)機(jī)[J].中國(guó)骨與關(guān)節(jié)雜志,2016,5(2):82-86.
[39] 何偉,劉予豪,周馳,等.非手術(shù)保髖治療非創(chuàng)傷性股骨頭壞死的臨床研究[J].中國(guó)中西醫(yī)結(jié)合雜志,2020,40(2):176-181.
[40] WEI Q S,HONG G J,YUAN Y J,et al.Huo Xue Tong Luo capsule,a vasoactive herbal formula prevents progression of asymptomatic osteonecrosis of femoral head:A prospective study[J].J Orthop Translat,2018,18:65-73.
[41] FANG B,LI Y,CHEN C,et al.Huo Xue Tong Luo capsule ameliorates osteonecrosis of femoral head through inhibiting lncRNA-Miat[J].J Ethnopharmacol,2019,238:111862.
[42] 中華醫(yī)學(xué)會(huì)骨科學(xué)分會(huì)關(guān)節(jié)外科學(xué)組.股骨頭壞死臨床診療規(guī)范[J].中國(guó)矯形外科雜志,2016,24(1):49-54.
相似文獻(xiàn)/References:
[1]陳雷雷,張穎.何偉教授采用中醫(yī)藥療法治療股骨頭壞死的經(jīng)驗(yàn)[J].中醫(yī)正骨,2015,27(10):74.
[2]徐西林,趙永蘭,張曉峰,等.活骨注射液髖關(guān)節(jié)腔灌注對(duì)兔股骨頭壞死模型
血管內(nèi)皮生長(zhǎng)因子表達(dá)的動(dòng)態(tài)影響[J].中醫(yī)正骨,2015,27(08):1.
XU Xilin,ZHAO Yonglan,ZHANG Xiaofeng,et al.Dynamic effect of intra-articular hip injection of Huogu injection on the expression of vascular endothelial growth factor in rabbit models with femur head necrosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(03):1.
[3]周勇,任菲菲,豐凡翔,等.血管內(nèi)皮生長(zhǎng)因子和骨形態(tài)發(fā)生蛋白2
在非創(chuàng)傷性股骨頭壞死不同區(qū)域的表達(dá)[J].中醫(yī)正骨,2015,27(08):7.
ZHOU Yong,REN Feifei,FENG Fanxiang,et al.Expressions of vascular endothelial growth factor and bone morphogenetic protein 2 in different zones of femoral head with non-traumatic osteonecrosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(03):7.
[4]鮑榮華,王國(guó)平,夏曉斌,等.鉭棒植入治療非創(chuàng)傷性股骨頭壞死的療效觀察[J].中醫(yī)正骨,2015,27(02):28.
[5]張兵,馬凰富,劉波,等.非創(chuàng)傷性股骨頭壞死的舌象定量研究[J].中醫(yī)正骨,2015,27(04):8.
ZHANG Bing,MA Huangfu,LIU Bo,et al.Quantitative study on tongue manifestation of patients with nontraumatic osteonecrosis of femoral head[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(03):8.
[6]李剛,程春生.股骨頭壞死血瘀證癥狀與平樂郭氏正骨方藥藥物組成
最大頻繁關(guān)聯(lián)模式挖掘[J].中醫(yī)正骨,2015,27(04):21.
LI Gang,CHENG Chunsheng.Maximal frequent association pattern mining for studying the relationship between BLOOD STASIS syndrome in patients with osteonecrosis of femoral head and drug components of Pingle Guo's orthopedics prescription[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(03):21.
[7]李文龍,梅沉成,杜貴強(qiáng),等.微創(chuàng)減壓植骨多孔鉭棒植入治療
ARCOⅡ期非創(chuàng)傷性缺血性股骨頭壞死[J].中醫(yī)正骨,2016,28(02):43.
[8]張磊,金紅婷,童培建.骨健口服液早期干預(yù)非創(chuàng)傷性股骨頭壞死的臨床研究[J].中醫(yī)正骨,2016,28(03):14.
ZHANG Lei,JIN Hongting,TONG Peijian.Clinical study on Gujian Koufuye(骨健口服液)for early intervention of nontraumatic osteonecrosis of femoral head[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2016,28(03):14.
[9]鮑榮華,王國(guó)平,夏曉斌,等.直接前入路微創(chuàng)全髖關(guān)節(jié)置換術(shù)治療晚期股骨頭壞死[J].中醫(yī)正骨,2016,28(03):61.
[10]張超,姚晨,沈計(jì)榮.微創(chuàng)髓芯減壓打壓支撐植骨術(shù)結(jié)合補(bǔ)腎活血湯口服治療ARCOⅡ、Ⅲ期股骨頭壞死的近期療效觀察[J].中醫(yī)正骨,2016,28(03):20.
ZHANG Chao,YAO Chen,SHEN Jirong.[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2016,28(03):20.